Cargando…

Structure of ABCB1/P-Glycoprotein in the Presence of the CFTR Potentiator Ivacaftor

ABCB1/P-glycoprotein is an ATP binding cassette transporter that is involved in the clearance of xenobiotics, and it affects the disposition of many drugs in the body. Conformational flexibility of the protein within the membrane is an intrinsic part of its mechanism of action, but this has made str...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barbieri, Alessandro, Thonghin, Nopnithi, Shafi, Talha, Prince, Stephen M., Collins, Richard F., Ford, Robert C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8703531/ https://www.ncbi.nlm.nih.gov/pubmed/34940424 http://dx.doi.org/10.3390/membranes11120923

Ejemplares similares

Investigation of the effects of the CFTR potentiator ivacaftor on human P-glycoprotein (ABCB1)
por: Lingam, Swathi, et al.
Publicado: (2017)

Novel features in the structure of P-glycoprotein (ABCB1) in the post-hydrolytic state as determined at 7.9 Å resolution
por: Thonghin, Nopnithi, et al.
Publicado: (2018)

Sweat rate analysis of ivacaftor potentiation of CFTR in non-CF adults
por: Kim, Jeeyeon, et al.
Publicado: (2018)

The use of ivacaftor in CFTR mutations resulting in residual functioning protein
por: Guigui, S., et al.
Publicado: (2016)

Impact of CFTR modulation with Ivacaftor on Gut Microbiota and Intestinal Inflammation
por: Ooi, Chee Y., et al.
Publicado: (2018)

Post-approval studies with the CFTR modulators Elexacaftor-Tezacaftor—Ivacaftor
por: Tümmler, Burkhard
Publicado: (2023)

Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment
por: Shaughnessy, Ciaran A., et al.
Publicado: (2021)

Cystic fibrosis drug ivacaftor stimulates CFTR channels at picomolar concentrations
por: Csanády, László, et al.
Publicado: (2019)

Ivacaftor in Omani children with cystic fibrosis caused by p.Ser549Arg CFTR mutation
por: Al Oraimi, Sumaya, et al.
Publicado: (2022)

Optimizing Nasal Potential Difference Analysis for CFTR Modulator Development: Assessment of Ivacaftor in CF Subjects with the G551D-CFTR Mutation
por: Rowe, Steven M., et al.
Publicado: (2013)

Author Correction: Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment
por: Shaughnessy, Ciaran A., et al.
Publicado: (2021)

CFTR Function Restoration upon Elexacaftor/Tezacaftor/Ivacaftor Treatment in Patient-Derived Intestinal Organoids with Rare CFTR Genotypes
por: Lefferts, Juliet W., et al.
Publicado: (2023)

Effects of Polyphenols on P-Glycoprotein (ABCB1) Activity
por: Singh, Kuljeet, et al.
Publicado: (2021)

CFTR bearing variant p.Phe312del exhibits function inconsistent with phenotype and negligible response to ivacaftor
por: Raraigh, Karen S., et al.
Publicado: (2022)

Ivacaftor-Mediated Potentiation of ABCB4 Missense Mutations Affecting Critical Motifs of the NBDs: Repositioning Perspectives for Hepatobiliary Diseases
por: Delaunay, Jean-Louis, et al.
Publicado: (2023)

In Vitro Rescue of the Bile Acid Transport Function of ABCB11 Variants by CFTR Potentiators
por: Mareux, Elodie, et al.
Publicado: (2022)

Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor
por: Bessonova, Leona, et al.
Publicado: (2018)

Impact of the CFTR-Potentiator Ivacaftor on Airway Microbiota in Cystic Fibrosis Patients Carrying A G551D Mutation
por: Bernarde, Cédric, et al.
Publicado: (2015)

In vitro functional rescue by ivacaftor of an ABCB11 variant involved in PFIC2 and intrahepatic cholestasis of pregnancy
por: Mareux, Elodie, et al.
Publicado: (2021)

The magnitude of ivacaftor effects on fluid secretion via R117H-CFTR channels: Human in vivo measurements
por: Char, Jessica E., et al.
Publicado: (2017)

CFTR potentiator ivacaftor protects against noise-induced hair cell loss by increasing Nrf2 and reducing oxidative stress
por: Wu, Fan, et al.
Publicado: (2023)

Elexacaftor-Tezacaftor-Ivacaftor: A Life-Changing Triple Combination of CFTR Modulator Drugs for Cystic Fibrosis
por: Bacalhau, Mafalda, et al.
Publicado: (2023)

Non‐pulmonary CFTR‐related symptom improvement with ivacaftor in p.Phe508del/p.Arg117His (7T) cystic fibrosis
por: Kuek, Stephanie L., et al.
Publicado: (2022)

P-glycoprotein (ABCB1) and Oxidative Stress: Focus on Alzheimer's Disease
por: Sita, Giulia, et al.
Publicado: (2017)

Rescue of multiple class II CFTR mutations by elexacaftor+tezacaftor+ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator
por: Laselva, Onofrio, et al.
Publicado: (2021)

From Ivacaftor to Triple Combination: A Systematic Review of Efficacy and Safety of CFTR Modulators in People with Cystic Fibrosis
por: Gramegna, Andrea, et al.
Publicado: (2020)

Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination
por: Veit, Guido, et al.
Publicado: (2020)

Ivacaftor modifies cystic fibrosis neutrophil phenotype in subjects with R117H residual function CFTR mutations
por: Hardisty, Gareth R., et al.
Publicado: (2021)

Functional Impact of ABCB1 Variants on Interactions between P-Glycoprotein and Methadone
por: Hung, Chin-Chuan, et al.
Publicado: (2013)

Towards Comprehension of the ABCB1/P-Glycoprotein Role in Chronic Myeloid Leukemia
por: Maia, Raquel C., et al.
Publicado: (2018)

Recent Advances on P-Glycoprotein (ABCB1) Transporter Modelling with In Silico Methods
por: Mora Lagares, Liadys, et al.
Publicado: (2022)

Cytochrome P450 3A4 Induction: Lumacaftor versus Ivacaftor Potentially Resulting in Significantly Reduced Plasma Concentration of Ivacaftor
por: Schneider, Elena K.
Publicado: (2018)

A Little CFTR Goes a Long Way: CFTR-Dependent Sweat Secretion from G551D and R117H-5T Cystic Fibrosis Subjects Taking Ivacaftor
por: Char, Jessica E., et al.
Publicado: (2014)

Identification and Empiric Evaluation of New Inhibitors of the Multidrug Transporter P-Glycoprotein (ABCB1)
por: Cheema, Yasmeen, et al.
Publicado: (2023)

Modeling long-term health outcomes of patients with cystic fibrosis homozygous for F508del-CFTR treated with lumacaftor/ivacaftor
por: Rubin, Jaime L., et al.
Publicado: (2019)

CFTR Modulator Therapy with Lumacaftor/Ivacaftor Alters Plasma Concentrations of Lipid-Soluble Vitamins A and E in Patients with Cystic Fibrosis
por: Sommerburg, Olaf, et al.
Publicado: (2021)

The Phosphodiesterase-5 Inhibitor Vardenafil Is a Potent Inhibitor of ABCB1/P-Glycoprotein Transporter
por: Ding, Pei-Rong, et al.
Publicado: (2011)

Cetuximab enhanced the efficacy of chemotherapeutic agent in ABCB1/P-glycoprotein-overexpressing cancer cells
por: Wang, Fang, et al.
Publicado: (2015)

Ivacaftor, not ivacaftor/lumacaftor, associated with lower pulmonary inflammation in preschool cystic fibrosis
por: Shanthikumar, Shivanthan, et al.
Publicado: (2022)

Long-Term Ivacaftor in People Aged 6 Years and Older with Cystic Fibrosis with Ivacaftor-Responsive Mutations
por: Pilewski, Joseph M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_i5uer8o2sp3fdg008vuvfie7t6